AU2007251239B2 - IL-1alpha immunization induces autoantibodies protective against atherosclerosis - Google Patents

IL-1alpha immunization induces autoantibodies protective against atherosclerosis Download PDF

Info

Publication number
AU2007251239B2
AU2007251239B2 AU2007251239A AU2007251239A AU2007251239B2 AU 2007251239 B2 AU2007251239 B2 AU 2007251239B2 AU 2007251239 A AU2007251239 A AU 2007251239A AU 2007251239 A AU2007251239 A AU 2007251239A AU 2007251239 B2 AU2007251239 B2 AU 2007251239B2
Authority
AU
Australia
Prior art keywords
mice
apoe
atherosclerosis
ppd
autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007251239A
Other languages
English (en)
Other versions
AU2007251239A1 (en
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xbiotech Inc
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of AU2007251239A1 publication Critical patent/AU2007251239A1/en
Application granted granted Critical
Publication of AU2007251239B2 publication Critical patent/AU2007251239B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Oxide Ceramics (AREA)
AU2007251239A 2006-05-15 2007-05-15 IL-1alpha immunization induces autoantibodies protective against atherosclerosis Active AU2007251239B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80002906P 2006-05-15 2006-05-15
US60/800,029 2006-05-15
PCT/IB2007/001264 WO2007132338A2 (en) 2006-05-15 2007-05-15 IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS

Publications (2)

Publication Number Publication Date
AU2007251239A1 AU2007251239A1 (en) 2007-11-22
AU2007251239B2 true AU2007251239B2 (en) 2013-08-22

Family

ID=38694276

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007251239A Active AU2007251239B2 (en) 2006-05-15 2007-05-15 IL-1alpha immunization induces autoantibodies protective against atherosclerosis

Country Status (9)

Country Link
US (1) US20090191149A1 (enExample)
EP (1) EP2021033B1 (enExample)
JP (1) JP2009537507A (enExample)
CN (1) CN101448528A (enExample)
AT (1) ATE551365T1 (enExample)
AU (1) AU2007251239B2 (enExample)
CA (1) CA2652274A1 (enExample)
ES (1) ES2384278T3 (enExample)
WO (1) WO2007132338A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1915620T3 (da) 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
HUE029003T2 (en) 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
EP2569640A1 (en) 2010-05-12 2013-03-20 The University of Birmingham Biomarker
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP6456015B2 (ja) * 2013-07-19 2019-01-23 国立大学法人三重大学 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物
CN105175504A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 血管性血友病因子抑制多肽及其应用
CN105175503A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 因子viii抑制多肽及其应用
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
AU2006298767A1 (en) * 2005-09-28 2007-04-12 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US6555579B2 (en) * 1998-08-13 2003-04-29 The Wistar Institute Methods for reducing atherosclerotic plaques
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
DK1915620T3 (da) * 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
AU2006298767A1 (en) * 2005-09-28 2007-04-12 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Svenson, M. et al. (2000) Journal of Immunological Methods, vol. 236, pp. 1-8 *

Also Published As

Publication number Publication date
EP2021033A2 (en) 2009-02-11
CN101448528A (zh) 2009-06-03
ATE551365T1 (de) 2012-04-15
US20090191149A1 (en) 2009-07-30
EP2021033A4 (en) 2010-02-24
WO2007132338A3 (en) 2008-06-12
WO2007132338A2 (en) 2007-11-22
EP2021033B1 (en) 2012-03-28
AU2007251239A1 (en) 2007-11-22
JP2009537507A (ja) 2009-10-29
ES2384278T3 (es) 2012-07-03
CA2652274A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
EP2021033B1 (en) Il-1-alpha for use in a method of treatment of atherosclerotic plaques.
US20120114598A1 (en) IL-1alpha immunization induces autoantibodies protective against atherosclerosis
Movsesyan et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine—a novel immunotherapeutic strategy
US11419924B2 (en) Immunotherapeutic compositions for the treatment of Alzheimer's disease
Klinman et al. DNA vaccines: safety and efficacy issues
Lima et al. Eosinophilic inflammation and airway hyper‐responsiveness are profoundly inhibited by a helminth (Ascaris suum) extract in a murine model of asthma
Town et al. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's β-amyloid1–42
Bates et al. Mucosal adjuvant activity of flagellin in aged mice
Timoshanko et al. Leukocyte-derived interleukin-1β interacts with renal interleukin-1 receptor I to promote renal tumor necrosis factor and glomerular injury in murine crescentic glomerulonephritis
JP6955324B2 (ja) 医薬化合物を評価するための新規動物モデル
Constantinescu et al. Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively
US20140227304A1 (en) Vaccines for preventing and treating alzheimer's disease
Klein et al. Engineering a safe monoclonal anti‐human IL‐2 that is effective in a murine model of food allergy and asthma
Babai et al. Depletion of peritoneal CD5+ B cells has no effect on the course of Leishmania major infection in susceptible and resistant mice
Wang et al. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis
US9173928B2 (en) DNA vaccine for Alzheimer's disease
Kedzierski et al. Decreased IL‐10 and IL‐13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by non‐persistent parasites
JP4673068B2 (ja) Ｔｈ１型アレルギー疾患治療用組成物
Ishii-Katsuno et al. Reduction of amyloid β-peptide accumulation in Tg2576 transgenic mice by oral vaccination
US6645486B1 (en) Method of treatment with IL-9 conjugate
Facincone et al. A novel murine model of late‐phase reaction of immediate hypersensitivity
Alderuccio et al. Organ-specific autoimmunity in granulocyte macrophage-colony stimulating factor (GM-CSF) deficient mice
US20190365785A1 (en) Inhibition of unfolded protein response for suppressing or preventing allergic reaction to food
Rempel et al. Failure of rIL-12 administration to inhibit established IgE responses in vivo is associated with enhanced IL-4 synthesis by non-B/non-T cells
Knopf et al. Interleukin-12 as an Adjuvant for an

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)